2 completed, 1 not yet recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow SCAI Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2a Study to Evaluate the Efficacy and Safety of SCAI-005 Ophthalmic Solution in Subjects With Neovascular Age-related Macular Degeneration SCAI-005 0.04% 2drops TID, SCAI-005 0.08% 2drops TID, Placebo 2drops TID - wetAMD, Age Related Macular Degeneration | Phase 2 | Not yet recruiting | SCAI Therapeutics | 50 | 2026-11-01 | 2026-05-26 |
| Clinical Study for the Evaluation of Safety and Tolerability of SCAI-005 Eye Drops SCAI-005 0.04% or placebo, SCAI-005 0.08% or placebo, SCAI-005 0.08% or placebo 2drops - Wet Age Related Macular Degeneration | Phase 1 | Completed | SCAI Therapeutics | 48 | 2025-05-29 | 2025-09-09 |
| Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis SCAI-001 0.01% eyedrop, SCAI-001 0.02% eyedrop, Restasis 0.05% eyedrop - Dry Eye Syndromes | Phase 2 | Completed | SCAI Therapeutics | 116 | 2023-01-05 | 2024-02-05 |
Dry Eye Syndromes (1) · Macular Degeneration (1)
Cyclosporins (1) · Ophthalmic Solutions (1)
South Korea (2)